Eli Lilly Other Long-Term Assets 2012-2026 | LLY
Eli Lilly other long-term assets from 2012 to 2026. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Eli Lilly other long-term assets for the quarter ending March 31, 2026 were $6.992B, a 22.24% increase year-over-year.
- Eli Lilly other long-term assets for 2025 were $6.992B, a 22.24% increase from 2024.
- Eli Lilly other long-term assets for 2024 were $5.72B, a 14.63% increase from 2023.
- Eli Lilly other long-term assets for 2023 were $4.99B, a 15.05% increase from 2022.
|
Eli Lilly Annual Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2025 | $6,992 |
| 2024 | $5,720 |
| 2023 | $4,990 |
| 2022 | $4,337 |
| 2021 | $4,083 |
| 2020 | $3,475 |
| 2019 | $2,871 |
| 2018 | $1,825 |
| 2017 | $1,708 |
| 2016 | $1,914 |
| 2015 | $2,221 |
| 2014 | $7,204 |
| 2013 | $2,213 |
| 2012 | $2,533 |
| 2011 | $2,493 |
|
Eli Lilly Quarterly Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2025-12-31 | $6,992 |
| 2025-09-30 | $6,432 |
| 2025-06-30 | $6,225 |
| 2025-03-31 | $6,075 |
| 2024-12-31 | $5,720 |
| 2024-09-30 | $5,122 |
| 2024-06-30 | $4,904 |
| 2024-03-31 | $4,708 |
| 2023-12-31 | $4,990 |
| 2023-09-30 | $4,912 |
| 2023-06-30 | $4,672 |
| 2023-03-31 | $4,488 |
| 2022-12-31 | $4,337 |
| 2022-09-30 | $4,536 |
| 2022-06-30 | $4,472 |
| 2022-03-31 | $4,285 |
| 2021-12-31 | $4,083 |
| 2021-09-30 | $3,710 |
| 2021-06-30 | $3,639 |
| 2021-03-31 | $3,756 |
| 2020-12-31 | $3,475 |
| 2020-09-30 | $3,079 |
| 2020-06-30 | $3,080 |
| 2020-03-31 | $3,045 |
| 2019-12-31 | $2,871 |
| 2019-09-30 | $2,194 |
| 2019-06-30 | $2,052 |
| 2019-03-31 | $1,963 |
| 2018-12-31 | $1,825 |
| 2018-09-30 | $2,009 |
| 2018-06-30 | $1,777 |
| 2018-03-31 | $1,747 |
| 2017-12-31 | $1,708 |
| 2017-09-30 | $2,198 |
| 2017-06-30 | $2,061 |
| 2017-03-31 | $2,020 |
| 2016-12-31 | $1,914 |
| 2016-09-30 | $2,279 |
| 2016-06-30 | $2,150 |
| 2016-03-31 | $2,245 |
| 2015-12-31 | $2,221 |
| 2015-09-30 | $2,890 |
| 2015-06-30 | $2,701 |
| 2015-03-31 | $2,489 |
| 2014-12-31 | $7,204 |
| 2014-09-30 | $2,339 |
| 2014-06-30 | $2,441 |
| 2014-03-31 | $2,339 |
| 2013-12-31 | $2,213 |
| 2013-09-30 | $1,321 |
| 2013-06-30 | $1,880 |
| 2013-03-31 | $2,096 |
| 2012-12-31 | $2,533 |
| 2012-09-30 | $2,388 |
| 2012-06-30 | $2,195 |
| 2012-03-31 | $2,093 |
| 2011-12-31 | $2,493 |
| 2011-09-30 | $2,216 |
| 2011-06-30 | $1,977 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $887.629B | $65.179B |
| Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |